ClinicalTrials.gg
Not yet recruitingNCT07079579Updated Jul 23, 2025

Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients

A Phase 4 interventional study of Enarodustat 2mg and Enarodustat 3mg in Renal Anemia in Non-dialysis Chronic Kidney Disease, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Anemia with a site in China — 33 open to participants now, 42 under way, 8 of them phase 3. Anemia · China.

Planned enrollment
46th of 97
120 · median 120
Started
2025
with 14 others
Phase 4
16 of 115
5 open now
Primary completion
2027-06
later than 28 of 41 live
Registered
103rd of 115
by date
Lead sponsor
5 of 115
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 115 studies in Anemia with a site in China, this one is the 46th largest by planned enrollment of the 97 interventional ones that give a count, is one of 15 that started in 2025, is one of 16 in phase 4, reaches primary completion later than 28 of the 41 other live ones, and was the 103rd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

33 of the 115 studies in Anemia with a site in China are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Anemia with a site in China, or all of them as a file.
02

Study summary

To evaluate the rationality of different initial doses of enarodustat for the treatment of anemia in ND-CKD patients

Read the detailed description

The eligible subjects screened will be stratified by treatment history and randomized to the 2, 3, 4 mg dose groups in a 1:1:1 ratio. After receiving the initial doses of 2, 3, 4 mg/day for 4 weeks, the subjects will enter a 12-week maintenance treatment period with a total of 7 scheduled visits.

03

Conditions studied

  • Renal Anemia in Non-dialysis Chronic Kidney Disease

Browse trials for

Keywords

  • Renal Anemia in Non-dialysis Chronic Kidney Disease
  • Enarodustat
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who meet all the following criteria can be enrolled in this study:

    1. Male or female patients aged 18-75 years (inclusive);
    2. Body weight: 45-100 kg (inclusive);
    3. Stage 3-5 non-dialysis CKD complicated with renal anemia during the screening period, with an of 10-60 mL/min/1.73 m2 (exclusive) (calculated by CKD-EPI equation);
    4. Criteria for levels at screening and baseline

    <!-- -->

    1. ESA-naïve population: Patients who do not receive ESA treatment in the past 12 weeks, with the Hb level greater than or equal to 70 g/L and less than 100 g/L;
    2. ESA-treated population: Patients who have received ESA treatment for at least 8 weeks, with the Hb level greater than or equal to 100 g/L and less than or equal to 120 g/L; 5.Female patients shall take measures during the study; Patients who voluntarily participate in the study and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Patients who meet any one of the following criteria shall be excluded from the study:

    1. Patients with SF ≤100 μg/L and TSAT ≤20% at screening;
    2. Patients who are expected to start renal replacement therapy in the next 6 months as judged by the investigator;
    3. Patients with systemic hematologic disorders (e.g., myelodysplastic syndrome and aplastic anemia, etc.) or non-CKD-related anemia (hemolytic anemia, hemorrhagic anemia, cancer related anemia, etc.);
    4. Patients with a 1.5-fold increase in serum creatinine during the screening period;
    5. Patients who have received hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) within 8 weeks before screening;
    6. Patients with polycystic kidney disease;
    7. Patients with poorly controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at the screening visit);
    8. Patients with congestive cardiac failure ( [NYHA] Class III or above) or unstable angina;
    9. Patients who have experienced myocardial infarction, , cerebral infarction (except asymptomatic cerebral infarction) or venous thromboembolism (pulmonary embolism or deep vein thrombosis) from 24 weeks before screening to the first dose of the drug;
    10. Patients with severe hepatobiliary disorders (e.g., or ALT >2.5 × (ULN) at the screening visit, patients with hepatic cirrhosis or total ≥1.5 × ULN at the screening visit);
    11. Patients who have received red blood cell transfusion from 12 weeks before screening to the first dose of the investigational drug;
    12. Patients who have received growth hormone, thyroid hormone, testosterone enanthate or methandienone from 12 weeks before screening to the first dose of the investigational drug;
    13. Patients who will undergo elective ophthalmic surgery in the next 6 months;
    14. Patients with severe hyperparathyroidism (e.g., iPTH ≥500 pg/mL at the screening visit);
    15. Patients with severe infections (e.g., active pulmonary tuberculosis and fungal infection, etc.);
    16. Patients suspected of having other non-infectious chronic inflammatory diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis and coeliac disease, etc.);
    17. Patients with a positive result for , or Treponema pallidum antibody, or with a positive result for and HBV DNA ≥1,000 U/mL;
    18. Patients with a history of malignant tumors (including hematological ) in the past 5 years;
    19. Patients with a history of severe drug allergy (e.g., anaphylactic shock) or to other HIF-PHIs;
    20. Patients with a history of drug or alcohol abuse in the past two years;
    21. Patients who have received other investigational drugs (or study drugs) or received investigational medical devices (or study devices) from 12 weeks before the screening visit to the first dose of the investigational drug, or are participating in other interventional clinical studies (medical behaviors beyond routine diagnosis and treatment, implemented for study purposes) and receiving treatment;
    22. Patients who are pregnant, lactating or have the possibility of pregnancy (based on the results of the pregnancy test at the screening visit, the investigator cannot rule out the possibility of pregnancy);
    23. Patients with any medical conditions that, in the investigator's judgment, may pose a safety risk, may confound efficacy or safety evaluation, or may interfere with their participation in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    2mg Enarodustat ESA-naïve

    ESA-naïve population initial phase:2mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

    Drug: Enarodustat 2mg

  • Experimental
    3mg Enarodustat ESA-naïve

    ESA-naïve population initial phase:3mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

    Drug: Enarodustat 3mg

  • Experimental
    4mg Enarodustat ESA-naïve

    ESA-naïve population initial phase:4mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

    Drug: Enarodustat 4mg

  • Experimental
    2mg Enarodustat ESA-treated

    ESA-treated population initial phase:2mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

    Drug: Enarodustat 2mg

  • Experimental
    3mg Enarodustat ESA-treated

    ESA-treated population initial phase:3mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

    Drug: Enarodustat 3mg

  • Experimental
    4mg Enarodustat ESA-treated

    ESA-treated population initial phase:4mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

    Drug: Enarodustat 4mg

Interventions

  • initial phase:2mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

  • initial phase:3mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

  • initial phase:4mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

06

What researchers measure

Primary outcomes

  1. Mean Hb level at Week 16 of treatment

    Time frame: week 16

Secondary outcomes

  1. Cumulative proportion of subjects with Hb levels of ≥100 g/L and ≤120 g/L at each visit

    Time frame: week 0,2,4,8,12,16

  2. Cumulative proportion of subjects with Hb levels of ≥110 g/L and <130 g/L at each visit

    Time frame: week 0,2,4,8,12,16

  3. ESA-treated group: cumulative proportion of subjects with Hb levels ±10 g/L from baseline at Weeks 12-16 of treatment;

    Time frame: week12- 16

  4. Hb levels at each visit

    Time frame: week 0,2,4,8,12,16

  5. Change in Hb level from baseline at each visit

    Time frame: week 0,2,4,8,12,16

  6. Dosage of administration of the investigational drug throughout the treatment period

    Time frame: 16 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Jun 2027, 22 months later.

Of 73 phase 4 interventional studies under Anemia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 48. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2025
First posted
Jul 23, 2025
StartEst.
Aug 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07079579
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Aug 2025 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 23, 2025

Study contacts

Xiangmei Chen, MD.&Ph.D
Contact
Xmchen301@126.com
13501261896

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enarodustat

Start the discussion